Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14197
UPID:
ICT1_HUMAN
Alternative names:
39S ribosomal protein L58, mitochondrial; Digestion substraction 1; Immature colon carcinoma transcript 1 protein; Peptidyl-tRNA hydrolase ICT1, mitochondrial
Alternative UPACC:
Q14197; B2RAD1; Q53HM7; Q53Y11
Background:
Large ribosomal subunit protein mL62, also known as 39S ribosomal protein L58, mitochondrial, plays a crucial role in mitochondrial protein synthesis. It acts as a codon-independent translation release factor, ensuring the termination of translation in mitochondria, which is vital for cellular energy production and metabolic functions.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL62 could open doors to potential therapeutic strategies.